Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Cutaneous Squamous Cell Carcinoma 1Carcinoma, Basal Cell 1

Interventions

Pemetrexed 18Carboplatin 16Cisplatin 14Paclitaxel 9Gemcitabine 7pembrolizumab 6Crizotinib 5osimertinib 4amivantamab 4Nivolumab 4Docetaxel 4lazertinib 3Vinorelbine 3Ipilimumab 3Afatinib 3selpercatinib 2lorlatinib 2durvalumab 2cemiplimab 2atezolizumab 2alectinib 2Gefitinib 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zenocutuzumab 1trastuzumab deruxtecan 1trametinib 1tepotinib 1telisotuzumab vedotin 1taletrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Carcinoma, Non-Small-Cell Lung × cemiplimab × Clear all
NCT03409614 2026-05-18

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Regeneron Pharmaceuticals

Phase 3 Completed
789 enrolled 32 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Regeneron Pharmaceuticals

Phase 3 Completed
712 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡